Abstract
CHRYSALIS is an open-label, single arm phase 1b/2 clinical trial conducted to assess safety and efficacy of amivantamab in patients with EGFR Ex20ins advanced NSCLC, after progressing on platinum doublet chemotherapy (CT). In absence of a comparator arm in CHRYSALIS, comparison of trial outcomes versus an external cohort of similar patients allows to quantify clinical benefits relative to treatments used in current clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
